BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 18048820)

  • 1. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption.
    Scope A; Agero AL; Dusza SW; Myskowski PL; Lieb JA; Saltz L; Kemeny NE; Halpern AC
    J Clin Oncol; 2007 Dec; 25(34):5390-6. PubMed ID: 18048820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption.
    Scope A; Lieb JA; Dusza SW; Phelan DL; Myskowski PL; Saltz L; Halpern AC
    J Am Acad Dermatol; 2009 Oct; 61(4):614-20. PubMed ID: 19646778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study.
    Leyden J; Thiboutot DM; Shalita AR; Webster G; Washenik K; Strober BE; Shupack J
    Arch Dermatol; 2006 May; 142(5):605-12. PubMed ID: 16702498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer.
    Jo JC; Hong YS; Kim KP; Lee JL; Kim HJ; Lee MW; Lim SB; Yu CS; Kim JC; Kim JH; Kim TW
    Eur J Dermatol; 2013; 23(1):77-82. PubMed ID: 23238388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
    Ocvirk J; Cencelj S
    J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic Effect of Oral Minocycline in Combination with Topical Steroid and Skin Care Against Panitumumab-induced Acneiform Rash in Metastatic Colorectal Cancer Patients.
    Yamada M; Iihara H; Fujii H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
    Anticancer Res; 2015 Nov; 35(11):6175-81. PubMed ID: 26504047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of tazarotene 0.1 % cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials.
    Shalita AR; Berson DS; Thiboutot DM; Leyden JJ; Parizadeh D; Sefton J; Walker PS; Gibson JR;
    Clin Ther; 2004 Nov; 26(11):1865-73. PubMed ID: 15639698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Acneiform eruptions induced by cetuximab].
    Walon L; Gilbeau C; Lachapelle JM
    Ann Dermatol Venereol; 2003 Apr; 130(4):443-6. PubMed ID: 12843857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical doxycycline foam 4% for prophylactic management of epidermal growth factor receptor inhibitor skin toxicity: an exploratory phase 2, randomized, double-blind clinical study.
    Shacham Shmueli E; Geva R; Yarom N; Hubert A; Keynan R; Kedem TH; Eini M; Tamarkin D; Shirvan M
    Support Care Cancer; 2019 Aug; 27(8):3027-3033. PubMed ID: 30607677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapy of severe cetuximab-induced acneiform eruptions with oral retinoid, topical antibiotic and topical corticosteroid].
    Wollenberg A; Moosmann N; Kroth J; Heinemann V; Klein E
    Hautarzt; 2007 Jul; 58(7):615-8. PubMed ID: 17146641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pilot clinical trial on the efficacy of prophylactic use of vitamin K1-based cream (Vigorskin) to prevent cetuximab-induced skin rash in patients with metastatic colorectal cancer.
    Pinta F; Ponzetti A; Spadi R; Fanchini L; Zanini M; Mecca C; Sonetto C; Ciuffreda L; Racca P
    Clin Colorectal Cancer; 2014 Mar; 13(1):62-7. PubMed ID: 24332355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Grover's disease induced by cetuximab.
    Tscharner GG; Bühler S; Borner M; Hunziker T
    Dermatology; 2006; 213(1):37-9. PubMed ID: 16778425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab-based therapy vs noncetuximab therapy in advanced or metastatic colorectal cancer: a meta-analysis of seven randomized controlled trials.
    Liu L; Cao Y; Tan A; Liao C; Mo Z; Gao F
    Colorectal Dis; 2010 May; 12(5):399-406. PubMed ID: 19508512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris.
    Thiboutot D; Arsonnaud S; Soto P
    J Drugs Dermatol; 2008 Jun; 7(6 Suppl):s3-10. PubMed ID: 18575220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cetuximab-induced cutaneous toxicity.
    Tomková H; Kohoutek M; Zábojníková M; Pospísková M; Ostrízková L; Gharibyar M
    J Eur Acad Dermatol Venereol; 2010 Jun; 24(6):692-6. PubMed ID: 19925598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti-Epidermal Growth Factor Receptor-Induced Acne-Like Rash: A Randomized Left-Right Comparative Evaluation (APPEARANCE).
    Chayahara N; Mukohara T; Tachihara M; Fujishima Y; Fukunaga A; Washio K; Yamamoto M; Nakata K; Kobayashi K; Takenaka K; Toyoda M; Kiyota N; Tobimatsu K; Doi H; Mizuta N; Marugami N; Kawaguchi A; Nishigori C; Nishimura Y; Minami H
    Oncologist; 2019 Jul; 24(7):885-e413. PubMed ID: 30890624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acneiform eruption induced by cetuximab.
    Cotena C; Gisondi P; Colato C; Girolomoni G
    Acta Dermatovenerol Croat; 2007; 15(4):246-8. PubMed ID: 18093454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies.
    Feldman SR; Werner CP; Alió Saenz AB
    J Drugs Dermatol; 2013 Apr; 12(4):438-46. PubMed ID: 23652892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients.
    de Noronha e Menezes NM; Lima R; Moreira A; Varela P; Barroso A; Baptista A; Parente B
    Eur J Dermatol; 2009; 19(3):248-51. PubMed ID: 19258241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer.
    Dascalu B; Kennecke HF; Lim HJ; Renouf DJ; Ruan JY; Chang JT; Cheung WY
    Support Care Cancer; 2016 Feb; 24(2):799-805. PubMed ID: 26184500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.